1 of 1
Story summary
- GlaxoSmithKline plc (GSK) reported that Mocertatug Rezetecan (Mo-Rez) reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients in early trials.
- GSK will move Mo-Rez to late-stage, global trials, including in the United Kingdom.
- The company aims for Mo-Rez to become a blockbuster and help reach a £40 billion sales target by 2031.
